- Amended Statement of Ownership (SC 13G/A)
28 February 2009 - 7:22AM
Edgar (US Regulatory)
|
UNITED
STATES
|
|
|
SECURITIES
AND EXCHANGE COMMISSION
|
|
|
Washington,
D.C. 20549
|
|
|
|
|
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment No. 1)*
XTL
Biopharmaceuticals Ltd.
(Name of Issuer)
American
Depository Receipts, each representing ten Ordinary Shares, par value NIS 0.02
(Title of Class of
Securities)
(CUSIP Number)
(Date of Event
Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
o
|
Rule 13d-1(b)
|
o
|
Rule 13d-1(c)
|
x
|
Rule 13d-1(d)
|
*The remainder of this cover page shall be filled out for a reporting
persons initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which would
alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
CUSIP No. 98386D109
|
|
|
1
|
Names of Reporting Persons
WAYNE P. ROTHBAUM
|
|
|
2
|
Check the Appropriate Box
if a Member of a Group (See Instructions)
|
|
|
(a)
|
o
|
|
|
(b)
|
o
|
|
|
3
|
SEC Use Only
|
|
|
4
|
Citizenship or Place of
Organization
United States
|
|
|
|
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With
|
5
|
Sole Voting Power
0 (See Item 4)
|
|
6
|
Shared Voting Power
0
|
|
7
|
Sole Dispositive Power
0 (See Item 4)
|
|
8
|
Shared Dispositive Power
0
|
|
|
9
|
Aggregate Amount
Beneficially Owned by Each Reporting Person
0 (See Item 4)
|
|
|
10
|
Check Box if the Aggregate
Amount in Row (9) Excludes Certain Shares (See Instructions)
x
|
|
|
11
|
Percent of Class
Represented by Amount in Row (9)
0%
|
|
|
12
|
Type of Reporting Person
(See Instructions)
IN
|
|
|
|
|
|
|
2
Item 1(a).
|
Name of Issuer:
The issuer of the securities to which this statement relates is XTL
BIOPHARMACEUTICALS LTD.
|
Item 1(b).
|
Address of Issuers
Principal Executive Offices:
The issuers principal executive offices are located at 750 Lexington Avenue,
20th Floor, New York, New York 10022.
|
|
Item 2(a).
|
Name of Person Filing:
Wayne P. Rothbaum.
|
Item 2(b).
|
Address of Principal
Business Office:
Wayne P. Rothbaum
c/o Quogue Capital LLC
1285 Avenue of the Americas, 35th Floor
New York, New York 10019.
|
Item 2(c).
|
Citizenship:
See Item 4 of cover pages.
|
Item 2(d).
|
Title of Class of
Securities:
American Depository Receipts, each representing ten Ordinary Shares, par
value NIS 0.02 (Ordinary Shares).
|
Item 2(e).
|
CUSIP Number:
The CUSIP number is 98386D109.
|
|
|
Item 3.
|
If this statement is filed pursuant
to Section 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person
filing is a:
|
|
The filing categories
pursuant to Rule 13d-1(b), 13d-2(b) and (c) are not applicable to each of the
filing persons.
|
3
Item 4.
|
Ownership.
|
|
(a)
|
Amount beneficially owned
as of December 31, 2008:
Mr. Rothbaum may be deemed
to beneficially own 0 Ordinary Shares as of December 31, 2008.
|
|
(b)
|
Percent of class as of
December 31, 2008:
0%
|
|
(c)
|
Number of shares as to
which such person has:
|
|
|
(i)
|
Sole power to vote or to
direct the vote:
See Item 5 of cover pages.
|
|
|
(ii)
|
Shared power to vote or to
direct the vote:
See Item 6 of cover pages.
|
|
|
(iii)
|
Sole power to dispose or
to direct the disposition of:
See Item 7 of cover pages.
|
|
|
(iv)
|
Shared power to dispose or
to direct the disposition of:
See Item 8 of cover pages.
|
|
Item 5.
|
Ownership of Five Percent or Less
of a Class.
|
If this statement is
being filed to report the fact that as of the date hereof the reporting
person has ceased to be the beneficial owner of more than five percent of the
class of securities, check the following
x
|
|
Item 6.
|
Ownership of More than Five Percent
on Behalf of Another Person.
|
Not applicable.
|
|
Item 7.
|
Identification and Classification
of the Subsidiary Which Acquired the Security Being Reported on By the Parent
Holding Company.
|
Not applicable.
|
|
Item 8.
|
Identification and Classification
of Members of the Group.
|
Not applicable.
|
|
Item 9.
|
Notice of Dissolution of Group.
|
Not applicable.
|
4
Item 10.
|
Certification.
|
Not applicable.
|
Signature
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
|
February 27, 2009
|
|
Dated
|
|
/s/ Wayne P. Rothbaum
|
|
Signature
|
|
Wayne P. Rothbaum
|
|
Name/Title
|
The original statement shall be signed by
each person on whose behalf the statement is filed or his authorized
representative. If the statement is signed on behalf of a person by his
authorized representative other than an executive officer or general partner of
the filing person, evidence of the representatives authority to sign on behalf
of such person shall be filed with the statement, provided, however, that a
power of attorney for this purpose which is already on file with the Commission
may be incorporated by reference. The name and any title of each person who
signs the statement shall be typed or printed beneath his signature.
Note
. Schedules filed in paper format shall include
a signed original and five copies of the schedule, including all exhibits.
See
Section 240.13d-7 for other parties for whom copies are to be sent.
|
ATTENTION
|
|
Intentional misstatements or
omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001.).
|
5
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024